Novo Nordisk AS (NVO)
68.03
-1.41
(-2.03%)
USD |
NYSE |
Apr 01, 16:00
68.19
+0.16
(+0.24%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 301.99B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -45.61% |
| Valuation | |
| PE Ratio | 20.73 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.215 |
| Price to Book Value | 15.09 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.099 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6692 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 52.65% |
Profile
Edit
| With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 07, 2025 |
| Last Earnings Release | Feb. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 31, 2025 |
Ratings
Profile
Edit
| With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 07, 2025 |
| Last Earnings Release | Feb. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 31, 2025 |